Human Apyrase to Disrupt Cancer Therapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$196,745.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA130192-01A2
Agency Tracking Number:
CA130192
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
192266141
Principal Investigator:
RIDONG CHEN
(314) 608-6932
RCHEN@NIDUSCENTER.COM
Business Contact:
(314) 812-8054
rchen@niduscenter.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an optimized human apyrase, APT102. With the Phase I grant support, we will determine whether APT102, alone or in combination with aspirin, is effective in inhibiting experimental spontaneous metastasis in mice. PUBLI C HEALTH RELEVANCE:Human apyrase represents a highly promising therapy for cancer treatment. We will determine whether the targeted apyrase, alone or in combination with aspirin, is effective in inhibiting experimental metastasis in mice.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government